Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

News

Earlier
Extra reg hurdle for AZ vax

Posted 22 December 2020 AM

AstraZeneca's Covid vaccine is one step closer to commercial supply in Australia with the Office of the Gene Regulator (OGTR) completing its initial risk assessment of the company's proposed activities, saying the GM vaccine "poses negligible risk."

As the activities which includes the import, transport, storage, and disposal of AZD1222 are classified as Dealings involving Intentional Release (DIR) of genetically modified organisms into the Australian environment, the OGTR's approval, along with TGA registration are required before the vaccine can be distributed.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
Biden and the MA agreement
'Global decisions' will influence ongoing negotiations
Special Report
PBAC March agenda
Every major and minor sub sorted by indication
Special Report
Aust Covid Vaccine Tracker
UPDATE: Distribution of two mRNA vaccines overseas